| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ITGAV; MSK8; VNRA; Integrin alpha-V; Vitronectin receptor subunit alpha; CD antigen CD51 |
| Entrez GeneID | 3685 |
| WB Predicted band size | Calculated MW: 116 kDa; Observed MW: 125 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human Integrin alpha V |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于Integrin alpha V抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**: *Targeting integrin αvβ3 with antibody-linked vaterite nanoparticles for molecular imaging of tumor angiogenesis*
**作者**: Murphy et al.
**摘要**: 研究开发了结合Integrin αvβ3抗体的纳米颗粒，用于肿瘤血管生成的分子影像学。实验表明，抗体偶联的纳米颗粒可特异性靶向肿瘤血管内皮细胞，增强体内成像对比度，为癌症诊断提供新工具。
---
2. **文献名称**: *Integrin αv in fibrosis: A key mediator in TGF-β signaling*
**作者**: Henderson et al.
**摘要**: 探讨Integrin αv抗体在抑制器官纤维化中的作用。通过阻断αv介导的TGF-β信号通路，抗体显著减轻小鼠模型中的肺和肝纤维化，提示其作为抗纤维化治疗的潜在药物。
---
3. **文献名称**: *Monoclonal antibody against integrin αv enhances anticancer drug delivery*
**作者**: Liu et al.
**摘要**: 该研究设计了一种靶向Integrin αv的单克隆抗体，通过增强化疗药物在肿瘤组织的富集，提高疗效并减少副作用。动物实验显示，抗体-药物偶联物显著抑制了多种实体瘤的生长。
---
这些文献涵盖了Integrin αV抗体在肿瘤靶向治疗、分子影像及纤维化疾病中的应用。如需更多文献或扩展内容，可进一步指定研究方向!
Integrin alpha V (αV) antibodies are tools used to study the function and expression of the αV subunit, a critical component of integrin heterodimeric receptors. Integrins are transmembrane proteins that mediate cell adhesion to the extracellular matrix (ECM) and regulate cellular processes like migration, proliferation, and survival. The αV subunit pairs with various β subunits (e.g., β1. β3. β5. β6. β8) to form receptors such as αVβ3 and αVβ5. which recognize ligands containing the Arg-Gly-Asp (RGD) motif. These receptors are implicated in angiogenesis, cancer metastasis, inflammation, and fibrosis.
Antibodies targeting integrin αV are designed to block or modulate its interactions with ECM proteins, signaling pathways, or partner β subunits. They are widely used in research to investigate αV's role in tumor progression, endothelial cell function, and immune responses. For example, αV-blocking antibodies can inhibit tumor angiogenesis by disrupting endothelial cell adhesion. In therapeutics, αV-targeting agents (e.g., monoclonal antibodies, peptide antagonists) have been explored in clinical trials for cancers and fibrotic diseases, though success has been limited by challenges like specificity and off-target effects.
Commercial αV antibodies vary in clonality, epitope specificity, and applications (e.g., flow cytometry, immunohistochemistry, functional assays). Their development continues to advance understanding of integrin biology and potential clinical interventions.
×
